

**TOXICOLOGICAL PROFILE FOR
POLYBROMINATED BIPHENYLS AND
POLYBROMINATED DIPHENYL ETHERS**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2004

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

A Toxicological Profile for PBBs and PBDEs, Draft for Public Comment, was released in 2002. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE,
Mailstop F-32
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.


Julie Louise Gerberding, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 7, 2003 (68 FR 63098). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792) and October 25, 2001 (66 FR 54014). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 498-0110	Fax: (770) 488-4178
E-mail: atsdric@cdc.gov	Internet: http://www.atsdr.cdc.gov

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Hana R. Pohl, M.D., Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Stephen Bosch, B.S.
Syracuse Research Corporation, Syracuse, NY

Richard J. Amata, M.S.
Syracuse Research Corporation, Syracuse, NY

Carol J. Eisenmann, Ph.D.
Sciences International, Inc., Alexandria, VA

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for polybrominated biphenyls and polybrominated diphenyl ethers. The panel consisted of the following members:

1. Martin Alexander, Ph.D., Professor, Department of Soil and Crop Sciences, Cornell University, Ithaca, New York;
2. Loren Koller, DVM, Ph.D., College of Veterinary Medicine, Oregon State University, 105 Magruder Hall, Corvallis, Oregon;
3. Christopher Metcalfe, Ph.D., Professor, Environmental and Resource Studies, Trent University, 1600 West Bank Drive, Peterborough, Ontario, Canada;
4. Larry W. Robertson, Ph.D., Professor, Graduate Center for Toxicology, University of Kentucky, Lexington, Kentucky; and
5. Lee R. Shull, Ph.D., Corporate Toxicology and Risk Assessment Practice Director, Montgomery, Watson, and Harza, Sacramento, California.

These experts collectively have knowledge of polybrominated biphenyls and polybrominated diphenyl ether's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
CONTENTS.....	xiii
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT—PBBs.....	1
1.1 WHAT ARE PBBs?	1
1.2 WHAT HAPPENS TO PBBs WHEN THEY ENTER THE ENVIRONMENT?.....	2
1.3 HOW MIGHT I BE EXPOSED TO PBBs?	3
1.4 HOW CAN PBBs ENTER AND LEAVE MY BODY?.....	3
1.5 HOW CAN PBBs AFFECT MY HEALTH?	4
1.6 HOW CAN PBBs AFFECT CHILDREN?.....	6
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PBBs?.....	7
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO PBBs?	7
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	8
1.10 WHERE CAN I GET MORE INFORMATION?.....	9
2. PUBLIC HEALTH STATEMENT—PBDEs	11
2.1 WHAT ARE PBDEs?	11
2.2 WHAT HAPPENS TO PBDEs WHEN THEY ENTER THE ENVIRONMENT?.....	12
2.3 HOW MIGHT I BE EXPOSED TO PBDEs?	13
2.4 HOW CAN PBDEs ENTER AND LEAVE MY BODY?.....	14
2.5 HOW CAN PBDEs AFFECT MY HEALTH?	15
2.6 HOW CAN PBDEs AFFECT CHILDREN?.....	16
2.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PBDEs?.....	17
2.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO PBDEs?	18
2.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	19
2.10 WHERE CAN I GET MORE INFORMATION?.....	20
3. RELEVANCE TO PUBLIC HEALTH—PBBs	23
3.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PBBs IN THE UNITED STATES	23
3.2 SUMMARY OF HEALTH EFFECTS	25
3.3 MINIMAL RISK LEVELS	33
4. RELEVANCE TO PUBLIC HEALTH—PBDEs.....	37
4.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PBDEs IN THE UNITED STATES	37

4.2	SUMMARY OF HEALTH EFFECTS	39
4.3	MINIMAL RISK LEVELS (MRLs).....	45
5.	HEALTH EFFECTS	57
5.1	INTRODUCTION	57
5.2	DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	60
5.2.1	Inhalation Exposure	62
5.2.1.1	Death	62
5.2.1.2	Systemic Effects.....	69
5.2.1.3	Immunological and Lymphoreticular Effects	77
5.2.1.4	Neurological Effects.....	78
5.2.1.5	Reproductive Effects.....	79
5.2.1.6	Developmental Effects	80
5.2.1.7	Cancer	80
5.2.2	Oral Exposure	80
5.2.2.1	Death	80
5.2.2.2	Systemic Effects.....	166
5.2.2.3	Immunological and Lymphoreticular Effects	194
5.2.2.4	Neurological Effects.....	199
5.2.2.5	Reproductive Effects.....	205
5.2.2.6	Developmental Effects	208
5.2.2.7	Cancer	216
5.2.3	Dermal Exposure	226
5.2.3.1	Death	226
5.2.3.2	Systemic Effects.....	229
5.2.3.3	Immunological and Lymphoreticular Effects	235
5.2.3.4	Neurological Effects.....	235
5.2.3.5	Reproductive Effects.....	236
5.2.3.6	Developmental Effects.....	236
5.2.3.7	Cancer	236
5.3	GENOTOXICITY.....	237
5.4	TOXICOKINETICS	241
5.4.1	Absorption	242
5.4.1.1	Inhalation Exposure	242
5.4.1.2	Oral Exposure	243
5.4.1.3	Dermal Exposure.....	245
5.4.2	Distribution	246
5.4.2.1	Inhalation Exposure	246
5.4.2.2	Oral Exposure	247
5.4.2.3	Dermal Exposure.....	253
5.4.2.4	Other Routes of Exposure	254
5.4.3	Metabolism	255
5.4.4	Elimination and Excretion	261
5.4.4.1	Inhalation Exposure	261
5.4.4.2	Oral Exposure	262
5.4.4.3	Dermal Exposure.....	266
5.4.4.4	Other Routes of Exposure	266
5.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models.....	266
5.5	MECHANISMS OF ACTION	269
5.5.1	Pharmacokinetic Mechanisms	269
5.5.2	Mechanisms of Toxicity	270

5.5.3	Animal-to-Human Extrapolations.....	284
5.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS.....	285
5.7	CHILDREN’S SUSCEPTIBILITY.....	291
5.8	BIOMARKERS OF EXPOSURE AND EFFECT.....	303
5.8.1	Biomarkers Used to Identify or Quantify Exposure to PBBs and PBDEs.....	304
5.8.2	Biomarkers Used to Characterize Effects Caused by PBBs and PBDEs.....	307
5.9	INTERACTIONS WITH OTHER CHEMICALS.....	310
5.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	311
5.11	METHODS FOR REDUCING TOXIC EFFECTS.....	313
5.11.1	Reducing Peak Absorption Following Exposure.....	314
5.11.2	Reducing Body Burden.....	314
5.11.3	Interfering with the Mechanism of Action for Toxic Effects.....	315
5.12	ADEQUACY OF THE DATABASE.....	316
5.12.1	Existing Information on Health Effects of PBBs and PBDEs.....	317
5.12.2	Identification of Data Needs.....	320
5.12.3	Ongoing Studies.....	340
6.	CHEMICAL AND PHYSICAL INFORMATION.....	345
6.1	CHEMICAL IDENTITY.....	345
6.2	PHYSICAL AND CHEMICAL PROPERTIES.....	355
7.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	367
7.1	PRODUCTION.....	367
7.2	IMPORT/EXPORT.....	370
7.3	USE.....	370
7.4	DISPOSAL.....	374
8.	POTENTIAL FOR HUMAN EXPOSURE.....	379
8.1	OVERVIEW.....	379
8.2	RELEASES TO THE ENVIRONMENT.....	383
8.2.1	Air.....	387
8.2.2	Water.....	392
8.2.3	Soil.....	394
8.3	ENVIRONMENTAL FATE.....	395
8.3.1	Transport and Partitioning.....	395
8.3.2	Transformation and Degradation.....	401
8.3.2.1	Air.....	401
8.3.2.2	Water.....	402
8.3.2.3	Sediment and Soil.....	407
8.3.2.4	Other Media.....	409
8.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT.....	409
8.4.1	Air.....	409
8.4.2	Water.....	412
8.4.3	Sediment and Soil.....	412
8.4.4	Other Environmental Media.....	416
8.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE.....	450
8.6	EXPOSURES OF CHILDREN.....	454
8.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES.....	456
8.8	ADEQUACY OF THE DATABASE.....	457
8.8.1	Identification of Data Needs.....	457
8.8.2	Ongoing Studies.....	465

9. ANALYTICAL METHODS	467
9.1 BIOLOGICAL MATERIALS	469
9.2 ENVIRONMENTAL SAMPLES	473
9.3 ADEQUACY OF THE DATABASE.....	476
9.3.1 Identification of Data Needs	477
9.3.2 Ongoing Studies	478
10. REGULATIONS AND ADVISORIES	479
11. REFERENCES	487
12. GLOSSARY	559

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B. USER'S GUIDE.....	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1
D. INDEX	D-1

LIST OF FIGURES

5-1.	Levels of Significant Exposure to Lower Brominated Diphenyl Ether—Inhalation	67
5-2.	Levels of Significant Exposure to Polybrominated Biphenyls—Oral	129
5-3.	Levels of Significant Exposure to Lower Brominated Diphenyl Ether—Oral	147
5.4.	Levels of Significant Exposure to Decabromodiphenyl Ether—Oral.....	160
5-5.	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	268
5-6.	Existing Information on Health Effects of PBBs.....	318
5-7.	Existing Information on Health Effects of PBDEs	319
8-1.	Frequency of NPL Sites with PBB Contamination.....	382

LIST OF TABLES

5-1.	Levels of Significant Exposure to Lower Brominated Diphenyl Ether—Inhalation	63
5-2.	Levels of Significant Exposure to Polybrominated Biphenyls—Oral	81
5-3.	Levels of Significant Exposure to Lower Brominated Diphenyl Ether—Oral	136
5-4.	Levels of Significant Exposure to Decabromodiphenyl Ether—Oral.....	150
5-5.	Levels of Significant Exposure to Polybrominated Biphenyls—Dermal	227
5-6.	Levels of Significant Exposure to Polybrominated Biphenyl Ethers—Dermal.....	230
5-7.	Genotoxicity of PBBs and PBDEs <i>In Vivo</i>	238
5-8.	Genotoxicity of PBBs and PBDEs <i>In Vitro</i>	239
5-9.	Ongoing Studies on the Health Effects of PBBs and PBDEs	341
6-1.	Chemical Identity of Polybrominated Biphenyl (PBB) and Polybrominated Diphenyl Ether (PBDE) Congeners.....	347
6-2.	Chemical Identity of Selected PBBs.....	353
6-3.	Chemical Identity of Technical PBDEs	356
6-4.	Physical and Chemical Properties of Selected PBBs.....	357
6-5.	Identified PBB Congeners in FireMaster® BP-6 and FireMaster® FF-1.....	359
6-6.	Physical and Chemical Properties of Some Technical PBDE Mixtures	362
6-7.	Physical and Chemical Properties of Some PBDE Congeners	364
6-8.	Composition of Commercial Brominated Diphenyl Ethers	366
7-1.	Total Market Demand of PBDEs by Region of the World in 2001	371
7-2.	Facilities that Produce, Process, or Use Decabromodiphenyl Ether.....	373
8-1.	Releases to the Environment from Facilities that Produce, Process, or Use Decabromobiphenyl Ether.....	392
8-2.	Concentrations (pg/m ³) of Several PBDEs in Air Samples	413
8-3.	Concentrations (ng/g) of Several PBDEs in Sediment and Suspended Particulate Samples.....	416

8-4.	Mean Concentration of Nine PBB Congeners in Lake Trout from the Great Lakes (pg/g Wet Weight)	420
8-5.	Tissue Levels of PBBs in Michigan Residents	424
8-6.	Concentrations (ng/g Dry Weight) of Several PBDEs in Biosolids (Sewage Sludge) and Effluent Samples	428
8-7.	Concentrations (ng/g Lipid Weight, Except as Noted) of Several PBDEs in Freshwater Fish Samples from the United States	430
8-8.	Concentrations (ng/g Lipid Weight, Except as Noted) of Several PBDEs in Freshwater Fish Samples from the Europe	433
8-9.	Concentrations (ng/g Lipid Weight) of Several PBDEs in Marine Aquatic Species	436
8-10.	Concentrations (ng/g Lipid Weight) of Several PBDEs in Marine Animals	440
8-11.	Concentrations (ng/g Lipid Weight) of Several PBDEs in Human Blood Samples	445
8-12.	Concentrations (ng/g Lipid Weight) of Several PBDEs in Human Adipose Tissue Samples	446
8-13.	Concentrations (ng/g Lipid Weight) of Several PBDEs in Human Breast Milk Samples	447
9-1.	Analytical Methods for Determining PBBs in Biological Materials	473
9-2.	Analytical Methods for Determining PBDEs in Biological Materials	474
9-3.	Analytical Methods for Determining PBBs in Environmental Samples	476
9-4.	Analytical Methods for Determining PBDEs in Environmental Samples	477
10-1.	Regulations and Guidelines Applicable to PBBs and PBDEs	482